Collagen News and Research

Latest Collagen News and Research

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Geographic information system software offers new way to study human remains

A common type of geographic mapping software offers a new way to study human remains. In a recent issue of the American Journal of Physical Anthropology, researchers describe how they used commercially available mapping software to identify features inside a human foot bone - a new way to study human skeletal variation.

26 Sep 2012

STAAR Surgical to participate in 88th Congress of the Society of Spanish Ophthalmologists

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it will be participating in the 88th Congress of the Society of Spanish Ophthalmologists being held in Barcelona from September 26 to 29.

26 Sep 2012

New computer program predicts most stable structures of nanometer-sized collagen

The human body is proficient at making collagen. And human laboratories are getting better at it all the time. In a development that could lead to better drug design and new treatments for disease, Rice University researchers have made a major step toward synthesizing custom collagen. Rice scientists who have learned how to make collagen - the fibrous protein that binds cells together into organs and tissues - are now digging into its molecular structure to see how it forms and interacts with biological systems.

26 Sep 2012

Alendronate decreases BMD loss in prostate cancer

Weekly administration of oral biphosphonate alendronate could reduce loss of bone mineral density in prostate cancer patients who start androgen-deprivation therapy, show study findings.

19 Sep 2012

U.K. scientists develop new test to catch drugs-cheats in sport

Scientists from three UK universities have developed a new test to catch drugs-cheats in sport.

15 Sep 2012

MicroRNA-145 gene therapy can drastically reduce severity and progression of atherosclerosis

Researchers at St. Michael's Hospital are one step closer to understanding why plaque bursts in coronary arteries and causes heart attacks.

11 Sep 2012

Morphological changes occur rapidly in response to cardiac injury

Cardiac injury leads to significant structural changes in the heart, including enlargement, excess formation of fibrous growth tissue, and abnormalities of the coronary vasculature. While associated factors have been targeted for therapeutic intervention, the results have been conflicting. Most studies have investigated these changes after six days of injury. However, advanced stages of remodeling have already begun by day seven following injury.

4 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012

Johns Hopkins team creates synthetic protein that can help locate tumors

Johns Hopkins researchers have created a synthetic protein that, when activated by ultraviolet light, can guide doctors to places within the body where cancer, arthritis and other serious medical disorders can be detected.

30 Aug 2012

BioTime amends license agreement with University of Utah for HyStem technology

BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Implanted cells' therapeutic properties depend on their shape

Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others.

16 Aug 2012

Cathepsins may attack one another instead of the bodily proteins

Researchers for the first time have shown that members of a family of enzymes known as cathepsins - which are implicated in many disease processes - may attack one another instead of the bodily proteins they normally degrade. Dubbed "cathepsin cannibalism," the phenomenon may help explain problems with drugs that have been developed to inhibit the effects of these powerful proteases.

15 Aug 2012

Scientists identify key factor that drives resistance to cancer drug

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.

6 Aug 2012

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen, Inc., today announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

31 Jul 2012

Burn wound MSCs potential source for skin grafting

Study findings suggest that burn wound eschar-derived mesenchymal cells represent a population of multipotent stem cells, which could be a new resource for engineering approaches to heal burn wounds.

30 Jul 2012

Researchers describe new human tissue dendritic cell with cross-presenting function

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source - providing a new potential target for vaccines for conditions such as cancer or Hepatitis B.

30 Jul 2012

Novel technique allows scientists to assay tumor invasion attributable to interstitial fluid

There are many factors that affect tumor invasion, the process where a tumor grows beyond the tissue where it first developed. While factors like genetics, tissue type and environmental exposure affect tumor metastasis and invasion, physical forces like fluid flow remain a poorly understood component of tumor invasion. A new video article in JoVE, the Journal of Visualized Experiments, describes a novel procedure that allows researchers to study and test the microenvironment of a growing tumor.

26 Jul 2012

Child who received first stem cell trachea transplant functioning well two years on

The first child stem cell-supported trachea transplant is functioning well two years on, according to an Article published Online First in The Lancet today. The follow-up of the procedure, carried out in 2010 at Great Ormond Street Hospital (GOSH), shows that the new organ has strengthened and does not appear to have induced any signs of rejection. The 13-year-old boy who received the transplant continues to breathe normally, has grown 11 cm in height and has returned to school. He does not require any anti-rejection therapy.

26 Jul 2012